360 related articles for article (PubMed ID: 22369442)
1. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
[TBL] [Abstract][Full Text] [Related]
2. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel for the treatment of prostate cancer.
Michielsen DP; Braeckman JG; Denis L
Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
[TBL] [Abstract][Full Text] [Related]
4. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
George DJ; Kantoff PW; Lin DW
Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
[TBL] [Abstract][Full Text] [Related]
5. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
Clarke NW
BJU Int; 2012 Oct; 110 Suppl 1():14-22. PubMed ID: 23046036
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging treatments in the management of castration-resistant prostate cancer.
Shapiro D; Tareen B
Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
9. [Castration-resistant prostate cancer: where are we going?].
Alcaraz A; Medina R; Maroto P; Climent MÁ; Castellano D; Carles J
Actas Urol Esp; 2012 Jun; 36(6):367-74. PubMed ID: 22188754
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in second-line treatment of castration-resistant prostate cancer.
Ong M; Winquist E
Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
[TBL] [Abstract][Full Text] [Related]
11. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
12. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
13. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Saad F; Miller K
Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
Beardsley EK; Chi KN
Curr Opin Support Palliat Care; 2008 Sep; 2(3):161-6. PubMed ID: 18685415
[TBL] [Abstract][Full Text] [Related]
15. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
16. Progress in emerging therapies for advanced prostate cancer.
Oudard S
Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF
BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221
[TBL] [Abstract][Full Text] [Related]
18. [Prostate cancer and chemotherapy: standards care and perspectives].
Hadjarab Y; Oudard S
Bull Cancer; 2012 Jul; 99 Suppl 1():S46-56. PubMed ID: 22516516
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
20. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
